Search - tctmd.com

Displaying 581 - 600 of 808

Sort: Relevancy | Date

Presentation TCT 2012

Is This the Next Breakthrough Therapy? Technology and Data Overview

Presenter: Joachim Schofer

October 25, 2012

Presentation TCT 2012

Future DCB Technologies: Challenges and Opportunities

Presenter: Juan Granada

October 25, 2012

Presentation TCT 2012

First-in-Man Results with a Novel Nanoparticle-Based Sirolimus-Coated Balloon in Coronary In-Stent Restenosis Lesions (Concept Medical)

Presenter: Suhas Lele

October 25, 2012

Presentation TCT 2012

FDA Perspectives

Presenter: Ashwani Sastry

October 25, 2012

Presentation TCT 2012

Development of a Drug-Coated Scoring Balloon: Preliminary Results from the PATENT-C First-in-Human Study

Presenter: Gary Gershony

October 25, 2012

Presentation TCT 2012

DCB Cost-Effectiveness Analysis: What Results Must Be Seen for Success in the United States?

Presenter: Duane Pinto

October 25, 2012

Presentation TCT 2012

Completed and Ongoing Clinical Trials

Presenter: Laura Mauri

October 25, 2012

Presentation TCT 2012

What's Needed for... Label Expansion (Bifurcations, Left Main, AMI, CTO, etc.)?

Presenter: Donald Cutlip

October 25, 2012

Presentation TCT 2012

What's Needed for... Bioabsorbable Polymer Delivery and Bioabsorbable Scaffolds?

Presenter: Ron Waksman

October 25, 2012

Presentation TCT 2012

What Evidence Is Necessary to Shorten DAPT After DES?

Presenter: Fausto Feres

October 25, 2012

Presentation TCT 2012

The VALENTINE Trials: Shellac-Based PCB Coating (Eurocor)

Presenter: Giuseppe Sangiorgi

October 25, 2012

Presentation TCT 2012

The PEPCAD Coronary Program: Iopromide-Based PCB Coating (B. Braun Medical)

Presenter: Bruno Scheller

October 25, 2012

Presentation TCT 2012

The LEVANT II US-Pivotal Study Update

Presenter: Dierk Scheinert

October 25, 2012

Presentation TCT 2012

The Invatec-Medtronic Peripheral PCB Program

Presenter: John Laird Jr

October 25, 2012

Presentation TCT 2012

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Lisette Okkels Jensen

October 25, 2012

Presentation TCT 2012

Role of DCB in SFA Intervention: Predictions Five Years into the Future

Presenter: Thomas Zeller

October 25, 2012

Presentation TCT 2012

Relevant New DES Features to Enhance Safety

Presenter: Alexandre Abizaid

October 25, 2012

Presentation TCT 2012

Paclitaxel Delivery and Tissue Effects: Similarities and Critical Differences with DES

Presenter: Renu Virmani

October 25, 2012

Presentation TCT 2012

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Patrick Serruys

October 25, 2012

Presentation TCT 2012

Impact of Paclitaxel Formulation on Drug Transfer, Tissue Pharmacokinetics, and Biological Activity

Presenter: Juan Granada

October 25, 2012

Advertisement

Is This the Next Breakthrough Therapy? Technology and Data Overview

Future DCB Technologies: Challenges and Opportunities

First-in-Man Results with a Novel Nanoparticle-Based Sirolimus-Coated Balloon in Coronary In-Stent Restenosis Lesions (Concept Medical)

FDA Perspectives

Development of a Drug-Coated Scoring Balloon: Preliminary Results from the PATENT-C First-in-Human Study

DCB Cost-Effectiveness Analysis: What Results Must Be Seen for Success in the United States?

Completed and Ongoing Clinical Trials

What's Needed for... Label Expansion (Bifurcations, Left Main, AMI, CTO, etc.)?

What's Needed for... Bioabsorbable Polymer Delivery and Bioabsorbable Scaffolds?

What Evidence Is Necessary to Shorten DAPT After DES?

The VALENTINE Trials: Shellac-Based PCB Coating (Eurocor)

The PEPCAD Coronary Program: Iopromide-Based PCB Coating (B. Braun Medical)

The LEVANT II US-Pivotal Study Update

The Invatec-Medtronic Peripheral PCB Program

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Role of DCB in SFA Intervention: Predictions Five Years into the Future

Relevant New DES Features to Enhance Safety

Paclitaxel Delivery and Tissue Effects: Similarities and Critical Differences with DES

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

Impact of Paclitaxel Formulation on Drug Transfer, Tissue Pharmacokinetics, and Biological Activity

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content